Peter Verhamme

35.5k total citations · 10 hit papers
350 papers, 13.1k citations indexed

About

Peter Verhamme is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Surgery. According to data from OpenAlex, Peter Verhamme has authored 350 papers receiving a total of 13.1k indexed citations (citations by other indexed papers that have themselves been cited), including 174 papers in Cardiology and Cardiovascular Medicine, 122 papers in Internal Medicine and 62 papers in Surgery. Recurrent topics in Peter Verhamme's work include Venous Thromboembolism Diagnosis and Management (122 papers), Atrial Fibrillation Management and Outcomes (99 papers) and Blood Coagulation and Thrombosis Mechanisms (41 papers). Peter Verhamme is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (122 papers), Atrial Fibrillation Management and Outcomes (99 papers) and Blood Coagulation and Thrombosis Mechanisms (41 papers). Peter Verhamme collaborates with scholars based in Belgium, Netherlands and United States. Peter Verhamme's co-authors include Jeffrey I. Weitz, Thomas Vanassche, Peter Sinnaeve, Hein Heidbüchel, Matthias Antz, Jonas Oldgren, Marco Alings, Werner Hacke, Marc Hoylaerts and Paulus Kirchhof and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Peter Verhamme

336 papers receiving 12.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

2017 1.1k citations Gary E. Raskob, Nick van Es et al. profile →
Idarucizumab for Dabigatran Reversal

2015 981 citations John W. Eikelboom, Peter Verhamme et al. profile →
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

2015 745 citations Hein Heidbüchel, Peter Verhamme et al. EP Europace profile →
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

2013 570 citations Hein Heidbüchel, Peter Verhamme et al. EP Europace profile →
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

2017 492 citations Jeffrey I. Weitz, Rupert Bauersachs et al. profile →
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

2014 455 citations Harry R. Büller, Gary E. Raskob et al. profile →
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial

2011 402 citations Peter Verhamme et al. profile →
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease

2018 269 citations John W. Eikelboom, Peter Verhamme et al. profile →
Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians

2017 254 citations Jonathan Douxfils, Walter Ageno et al. Journal of Thrombosis and Haemostasis profile →
Abelacimab for Prevention of Venous Thromboembolism

2021 180 citations Peter Verhamme, Annelise Segers et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Verhamme Belgium	53	7.1k	5.5k	2.3k	1.8k	1.7k	350	13.1k
Francesco Dentali Italy	37	7.1k 1.0×	7.9k 1.4×	3.6k 1.5×	1.4k 0.7×	1.8k 1.1×	194	13.4k
Suzanne C. Cannegieter Netherlands	55	7.1k 1.0×	7.4k 1.3×	2.9k 1.3×	1.6k 0.9×	2.7k 1.6×	333	14.3k
Stavros Konstantinides Germany	68	9.4k 1.3×	11.4k 2.1×	2.7k 1.1×	4.7k 2.6×	1.6k 1.0×	452	18.3k
Kenneth A. Bauer United States	60	6.4k 0.9×	7.6k 1.4×	3.0k 1.3×	878 0.5×	5.4k 3.2×	201	13.6k
Bernd Jilma Austria	64	4.8k 0.7×	2.1k 0.4×	2.4k 1.0×	2.5k 1.3×	4.4k 2.7×	562	16.7k
Beverley J. Hunt United Kingdom	65	3.4k 0.5×	4.5k 0.8×	4.7k 2.0×	2.0k 1.1×	5.7k 3.5×	340	19.3k
Jerrold H. Levy United States	76	6.8k 1.0×	4.6k 0.8×	6.2k 2.6×	3.0k 1.6×	3.4k 2.0×	472	23.6k
Jean M. Connors United States	41	2.7k 0.4×	3.5k 0.6×	1.7k 0.7×	790 0.4×	1.6k 0.9×	228	8.9k
Emmanuel J. Favaloro Australia	58	3.8k 0.5×	3.5k 0.6×	3.2k 1.4×	752 0.4×	7.9k 4.8×	704	15.9k
Richard H. White United States	61	5.5k 0.8×	8.5k 1.5×	4.0k 1.7×	1.2k 0.7×	2.6k 1.5×	242	15.9k

Countries citing papers authored by Peter Verhamme

Since Specialization

Citations

This map shows the geographic impact of Peter Verhamme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Verhamme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Verhamme more than expected).

Fields of papers citing papers by Peter Verhamme

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Verhamme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Verhamme. The network helps show where Peter Verhamme may publish in the future.

Co-authorship network of co-authors of Peter Verhamme

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Verhamme. A scholar is included among the top collaborators of Peter Verhamme based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Verhamme. Peter Verhamme is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Prandoni, Paolo, Meg Fluharty, Sebastian Schellong, et al.. (2025). Sex differences in venous thromboembolism outcomes: findings from the GARFIELD-VTE registry. European Journal of Internal Medicine. 144. 106492–106492.

Geet, Chris Van, Peter Verhamme, Thomas Vanassche, et al.. (2025). Clinical utility of panel-based genetic sequencing for von Willebrand disease. Research and Practice in Thrombosis and Haemostasis. 9(2). 102730–102730. 2 indexed citations

Norton, Gavin R., Lucas S. Aparicio, Yu‐Ling Yu, et al.. (2024). Mortality and Cardiovascular End Points In Relation to the Aortic Pulse Wave Components: An Individual-Participant Meta-Analysis. Hypertension. 81(5). 1065–1075. 3 indexed citations

Peetermans, Marijke, et al.. (2023). Peptidylarginine deiminase 4 and ADAMTS13 activity in Staphylococcus aureus bacteraemia. Philosophical Transactions of the Royal Society B Biological Sciences. 378(1890). 20230042–20230042. 6 indexed citations

Vanassche, Thomas, et al.. (2023). Therapy and guideline adherence at a multidisciplinary hypertension clinic: A prospective, observational study. Vascular Pharmacology. 154. 107271–107271. 1 indexed citations

Demchuk, Andrew M., Patrick Yue, Elena Zotova, et al.. (2021). Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. Stroke. 52(6). 2096–2105. 43 indexed citations

Vandenbriele, Christophe, Lisa Dannenberg, Tim Balthazar, et al.. (2020). Optimal antithrombotic regimen in patients with cardiogenic shock on ImpellaTM mechanical support: less might be more. European Heart Journal. 41(Supplement_2). 4 indexed citations

Harenberg, Job, Jan Beyer‐Westendorf, Mark Crowther, et al.. (2019). Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial. Thrombosis and Haemostasis. 120(1). 132–140. 25 indexed citations

Mulder, Frits I., Marcello Di Nisio, Cihan Ay, et al.. (2019). Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal. 55(2). 1901697–1901697. 31 indexed citations

10.

Peetermans, Marijke, Severien Meyers, Laurens Liesenborghs, et al.. (2019). Von Willebrand factor and ADAMTS13 impact on the outcome of Staphylococcus aureus sepsis. Journal of Thrombosis and Haemostasis. 18(3). 722–731. 29 indexed citations

11.

Wei, Fang‐Fei, Sander Trenson, Pierre Monney, et al.. (2018). Epidemiological and histological findings implicate matrix Gla protein in diastolic left ventricular dysfunction. PLoS ONE. 13(3). e0193967–e0193967. 13 indexed citations

12.

Wei, Fang‐Fei, Anke Raaijmakers, Zhen‐Yu Zhang, et al.. (2018). Association between cognition and the retinal microvasculature in 11-year old children born preterm or at term. Early Human Development. 118. 1–7. 21 indexed citations

13.

Heidbüchel, Hein, Peter Verhamme, Marco Alings, et al.. (2016). Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. European Heart Journal. 38(27). ehw058–ehw058. 188 indexed citations

14.

Brekelmans, Marjolein, Walter Ageno, Ludo F.M. Beenen, et al.. (2016). Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. The Lancet Haematology. 3(9). e437–e445. 25 indexed citations

15.

Maervoet, Johan, et al.. (2015). Cost effectiveness of Rivaroxaban versus low molecular weight heparin and vitamin K antagonists for the treatment of deep-vein thrombosis in the Belgian healthcare setting. DIAL (Catholic University of Leuven). 3(1). 452–461.

16.

Pollack, Charles V., Paul Reilly, Peter Verhamme, et al.. (2015). Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions. Journal of Thrombosis and Haemostasis. 13. 85–85. 2 indexed citations

17.

Heidbüchel, Hein, Peter Verhamme, Marco Alings, et al.. (2015). Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. EP Europace. 17(10). 1467–1507. 745 indexed citations breakdown →

18.

Peetermans, Marijke, et al.. (2014). Monitoring and reversal strategies for new oral anticoagulants. Expert Review of Cardiovascular Therapy. 13(1). 95–103. 29 indexed citations

19.

Riva, Nicoletta, Walter Ageno, Sam Schulman, et al.. (2013). Antithrombotic treatment of splanchnic vein thrombosis in the ISTH international registry: results of 6-month follow-up. Journal of Thrombosis and Haemostasis. 11. 87–88. 1 indexed citations

20.

Remoortel, Hans Van, Miek Hornikx, Daniël Langer, et al.. (2013). Risk Factors and Comorbidities in the Preclinical Stages of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 189(1). 30–38. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact